Ant venom allergen

Ant venom allergens are a heterogeneous group of proteins and peptides found in the venom of various ant species, most notably fire ants (Solenopsis invicta) and jumper ants (Myrmecia pilosula). These allergens include enzymes such as phospholipase A1 (Sol i 1) and hyaluronidase, as well as non-enzymatic proteins like the Sol i 2-4 family and Antigen 5-related proteins (Sol i 3) (Hoffman, 2006; UniProt). Biologically, these molecules function as defensive toxins that disrupt host tissues through enzymatic degradation or membrane interference (Touchard et al., 2016). In sensitized individuals, exposure to these allergens triggers an IgE-mediated immune response, which can manifest as severe local reactions or life-threatening systemic anaphylaxis (StatPearls). While they are the primary cause of disease, these allergens also serve as the active components in venom immunotherapy (VIT), where they are used to desensitize patients by modulating T-cell responses and inducing protective IgG4 antibodies (EAACI Guidelines, 2018). Current clinical management relies on these allergens for both component-resolved diagnostics and the formulation of therapeutic extracts used in long-term desensitization protocols.

Other names

Ant venom allergensFormicidae venom allergensFire ant venom allergensBull ant venom allergensHymenoptera venom allergens (Ant)

Venom immunotherapy (VIT) utilizes these allergens to induce immune tolerance by promoting the expansion of regulatory T cells (Tregs), shifting the cytokine profile from Th2 to Th1, and stimulating the production of allergen-specific IgG4 antibodies that compete with IgE for allergen binding (Sturm et al., 2018).